Article
Twist1 Influences the Expression of Leading Members of the IL-17 Signaling Pathway in HER2-Positive Breast Cancer Cells
Registro en:
PIRES, Bruno R. B. et al. Twist1 Influences the Expression of Leading Members of the IL-17 Signaling Pathway in HER2-Positive Breast Cancer Cells. International Journal of Molecular Sciences, v. 22, 12144, p. 1 - 17, Nov. 2021.
1422-0067
10.3390/ijms222212144
Autor
Pires, Bruno R. B.
Binato, Renata
Ferreira, Gerson M.
Corrêa, Stephany
Du Rocher, Bárbara
Bulzico, Daniel
Crocamo, Susanne
Santos, Everton Cruz dos
Lima, Luize G.
Abdelhay, Eliana Saul Furquim Werneck
Resumen
Abstract: Breast cancer (BC) is a heterogeneous disease composed of multiple subtypes with different
molecular characteristics and clinical outcomes. The metastatic process in BC depends on the
transcription factors (TFs) related to epithelial-mesenchymal transition (EMT), including the master
regulator Twist1. However, its role beyond EMT in BC subtypes remains unclear. Our study aimed to
investigate the role of Twist1, beyond EMT, in the molecular subtypes of BC. In patients, we observed
the overexpression of TWIST1 in the HER2+ group. The silencing of TWIST1 in HER2+ BC cells
resulted in the upregulation of 138 genes and the downregulation of 174 genes compared to control
cells in a microarray assay. In silico analysis revealed correlations between Twist1 and important
biological processes such as the Th17-mediated immune response, suggesting that Twist1 could be
relevant for IL-17 signaling in HER2+ BC. IL-17 signaling was then examined, and it was shown that
TWIST1 knockdown caused the downregulation of leading members of IL-17 signaling pathway.
Taken together, our findings suggest that Twist1 plays a role on IL-17 signaling in HER2+ BC.